Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

@article{Smith2006LongtermCO,
  title={Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.},
  author={Kenneth G C Smith and Rachel Bronwen Jones and Sharon Burns and David R. W. Jayne},
  journal={Arthritis and rheumatism},
  year={2006},
  volume={54 9},
  pages={2970-82}
}
OBJECTIVE Current treatments for systemic lupus erythematosus (SLE) and vasculitis contribute to mortality and incapacity and are only partially effective; thus, newer therapies are clearly needed. Depletion of B cells has led to disease control in patients with autoimmune disorders. We sought to assess the long-term efficacy and safety of a B cell-depleting therapy in patients with SLE and patients with vasculitis. METHODS In a prospective study with a median followup of 24 months, 11… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 153 extracted citations

Similar Papers

Loading similar papers…